Ceftolozane/Tazobactam Dosing for Pseudomonas Pneumonia and Bacteremia
For adults with Pseudomonas aeruginosa pneumonia and bacteremia, use ceftolozane/tazobactam 3 g (2 g ceftolozane/1 g tazobactam) IV every 8 hours, infused over 1 hour, with renal dose adjustments as needed.
Standard Dosing for Hospital-Acquired/Ventilator-Associated Pneumonia
The higher dose of ceftolozane/tazobactam is specifically indicated for pneumonia due to the approximately 50% penetration ratio from plasma to epithelial lining fluid 1, 2. This requires doubling the standard dose used for complicated urinary tract infections or intra-abdominal infections to achieve adequate lung concentrations.
- Standard dose: 3 g (2 g/1 g) IV every 8 hours, infused over 1 hour
- Duration: 10-14 days for hospital-acquired pneumonia and bloodstream infection 1
- Infusion time: 1 hour (standard) or extended 3-hour infusion may be considered for optimization 1
The 2022 guidelines for multidrug-resistant organisms specifically recommend this 3 g dose for hospital-acquired or ventilator-associated pneumonia caused by difficult-to-treat Pseudomonas aeruginosa 1. This is supported by pharmacokinetic/pharmacodynamic modeling showing that the 3 g dose achieves >90% probability of target attainment in epithelial lining fluid against pathogens with MIC ≤8 mg/L 2.
Renal Dose Adjustments
Ceftolozane/tazobactam requires careful renal dosing adjustments based on creatinine clearance:
Normal Renal Function (CrCl >50 mL/min)
- 3 g IV every 8 hours
Moderate Renal Impairment (CrCl 30-50 mL/min)
- Loading dose: 3 g IV
- Maintenance: 1.5 g IV every 8 hours
Severe Renal Impairment (CrCl 15-29 mL/min)
- Loading dose: 2.25 g IV
- Maintenance: 750 mg IV every 8 hours
End-Stage Renal Disease on Intermittent Hemodialysis
- Loading dose: 1.5 g (1 g/0.5 g) IV
- Maintenance: 300 mg (200 mg/100 mg) IV every 8 hours 3, 4, 5
- Administer after hemodialysis on dialysis days
A 2023 pharmacokinetic study specifically validated this ESRD dosing regimen, demonstrating >90% probability of target attainment in both plasma and epithelial lining fluid 3. A case report confirmed clinical success with this regimen in a patient with MDR Pseudomonas bacteremia on hemodialysis 4, 5.
Continuous Renal Replacement Therapy (CRRT)
- 1.5 g IV every 8 hours as extended infusion
- A case report demonstrated adequate drug levels (Cmin 31.63 μg/ml, eight times the susceptibility breakpoint) with this dosing during continuous venovenous hemofiltration 6
Combination Therapy Considerations
For patients in septic shock or at high risk of death (mortality risk >25%), consider combination therapy with a second antipseudomonal agent 7. The 2016 IDSA/ATS guidelines recommend:
- Combination therapy using 2 antibiotics to which the isolate is susceptible (weak recommendation)
- Once septic shock resolves and susceptibilities are known, de-escalate to monotherapy
- Avoid aminoglycoside monotherapy (strong recommendation)
However, for patients not in septic shock with known susceptibilities, monotherapy with ceftolozane/tazobactam is appropriate if the organism is susceptible (strong recommendation) 7.
Important Clinical Considerations
Resistance Development
Ceftolozane/tazobactam has a lower rate of resistance development (10%) compared to ceftazidime-avibactam (40%) in patients with MDR Pseudomonas bacteremia or pneumonia 8. This makes it a preferred agent when both are options.
Susceptibility Testing
Always obtain antimicrobial susceptibility testing to guide definitive therapy 1, 7. The choice of antibiotic should be based on susceptibility results and patient-specific factors including renal function.
Therapeutic Drug Monitoring
Consider therapeutic drug monitoring in critically ill patients, particularly those with:
- Augmented renal clearance
- Severe sepsis/septic shock
- Altered volume of distribution
- Renal replacement therapy 7
Common Pitfalls to Avoid
- Using the 1.5 g dose for pneumonia: This is inadequate due to poor lung penetration; always use 3 g for respiratory infections
- Forgetting renal adjustments: Ceftolozane is renally cleared; failure to adjust can lead to toxicity
- Prolonged combination therapy: If shock resolves, de-escalate to monotherapy to reduce toxicity risk
- Inadequate duration: Complete 10-14 days for pneumonia with bacteremia; shorter courses risk relapse 1